Fabrizio Messina

ORCID: 0009-0002-6383-2915 · 1 paper in corpus

rct 2024

Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study

BMC women's health ·doi:10.1186/s12905-024-03188-8

BACKGROUND: The SCHUMANN study evaluated the efficacy and safety of the selective P2 × 3 antagonist eliapixant in patients with endometriosis-associated pelvic pain (EAPP). METHODS: SCHUMANN was a randomized, placebo- and active comparator…